Pylarify approved by NCCN for Pluvicto - Advanced Prostate...

Advanced Prostate Cancer

15,782 members19,172 posts

Pylarify approved by NCCN for Pluvicto

Tall_Allen profile image

The National Comprehensive Cancer Network (NCCN) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) have now updated their guidelines to allow use of Pylarify PSMA PET to qualify for Pluvicto (177Lu-PSMA617).

As you may know, the FDA only approved 68Ga-PSMA-11 PET to qualify for Pluvicto. That's because the FDA can only approve what was used in the VISION trial. But Pylarify is more widely available. Insurance companies and Medicare may still deny Pluvicto if there is only a Pylarify scan, but they will probably reverse their decision with the new NCCN guideline.

Novartis is still 6 weeks off from supplying Pluvicto.

24 Replies

Thank-you TA. Very good info…

Dumb question, what is Pluvicto?

Woodstock82 profile image
Woodstock82 in reply to cesces

Brand name for 177Lu-PSMA therapy.

cesces profile image
cesces in reply to Woodstock82

"Pylarify PSMA PET to qualify for Pluvicto (177Lu-PSMA617)"


May I ask what Pylarify is if Pluvicto is a psma pet scan?

Tall_Allen profile image
Tall_Allen in reply to cesces

Pluvicto (177Lu-PSMA617) is not a PET scan. It is a treatment for prostate cancer.

cesces profile image
cesces in reply to Woodstock82

May I ask what Pylarify is if Pluvicto is a psma pet scan contrast be agent?

Tall_Allen profile image
Tall_Allen in reply to cesces

Pylarify is a PSMA PET scan. Pluvicto is a treatment. To qualify for Pluvicto, one must demonstrate that one is PSMA-avid on a PSMA PET scan.

Gabby643 profile image
Gabby643 in reply to Tall_Allen

Thanks again T A.

Tall_Allen profile image
Tall_Allen in reply to cesces

It helps if you read the post (end of first paragraph).

Good news! Glad to hear it. Thanks.

Thank you TA. I think I read that pluvicto is not being manufactured in the US because of some quality issues - do you know anything about that, and when they may start again?

It is a global delay for at least 6 weeks.

Thank you, TA

That’s so exciting. Five years ago, I was one of the early folks who were newly diagnosed for whom insurance would cover abiraterone while still castrate sensitive. One day, I suspect I’ll need a next option so this is wonderful. Thanks, TA! ✌️ DougNOLA

@cesces Basically you can't use the Pluvicto treatment until you can see the cancer on a PSMA PET Scan because the Pylarify "tracer" drug they inject in you binds to PSMA. If nothing shows up on the scan, it doesn't mean you don't necessarily have active cancer, it's just not large enough to see on the scan. The Pluvicto binds to the cancer the same way as the Pylarify does. So there's nothing (or very little) for the Pluvicto to bind to if there's nothing on the Pylarify PSMA PET Scan. The good news is Pylarify is a little more sensitive than the older Ga68 PSMA so patients might be able to get the Pluvicto treatment a little earlier now.

@Tall_Bill Really appreciate all you do to keep people up to date. Hopefully Radioligand treatments like Pluvicto will be improved in the coming years as to date, it seems it significantly helps with impeding progression of distant metastases but unfortunately if I recall the time to cancer mortality was lengthened by an average of only 4 months. I believe the trial though was limited to people at a very late stage though? It seems like Radioligand and Immunotherapy are the areas we can look forward to further advancements and hopefully one day either there will be a cure, or, the disease can be managed indefinitely like HIV. The latter may come sooner than we might expect. I am anxious to see results from further trials where treatments like Pluvicto are used at the very first sign of PSMA PET detected recurrence.

MateoBeach profile image
MateoBeach in reply to jazj

Good post and clear views jazj. I am getting a novel form of Lu PSMA monoclonal antibody radioligand treatment tomorrow morning here in Perth where I flew yesterday to receive this. It is not in a trial. It is unproven and pre-trial as I am HSPC oligometastatic with all identified sites already treated with SBRT a month ago. Why am I doing this? I am preparing a post for later tonight to address that very question . I will be interesting your take. Regards. MateoBeach

jazj profile image
jazj in reply to MateoBeach

Read your post. I would do exactly the same thing in your situation. Takes some courage! But you could provide extremely valuable information on how patients responds doing Radioligand treatment earlier than later.

Am I correct in assuming the Lu177PSMA617 pluvicto would still only be used for CRPC and not CSPC

Tall_Allen profile image
Tall_Allen in reply to KocoPr

The problem in production is for the Lu-177 isotope. It doesn't matter what purpose it's used for.

TJGuy profile image
TJGuy in reply to KocoPr

Yes but clinical trials are in progress for CSPC. Results in one year.

Thanks TA


Thanks TA. Gave us very useful info.

pluvicto, A Walt Disney character (Pluto's twin).....

Good Luck, Good Health and Good Humor.

j-o-h-n Thursday 05/12/2022 6:02 PM DST

The splash clinical trial, is using a competitor's similar product for PSMA therapy with reportably less side effects to saliva glands, kidneys.Over a year behind, but a competitor may help keep prices down, and avoid supply issues.

You may also like...